Incidence and risk factors for verrucae in women

AIDS

Volumn 22, Issue 10, 2008, Pages 1213-1219

  Dolev, Jacqueline C ^a   Maurer, Toby ^a   Springer, Gayle ^b   Glesby, Marshall J ^c   Minkoff, Howard ^d   Connell, Casey ^e   Young, Mary ^f   Schowalter, Karlene ^g   Cox, Christopher ^b   Hessol, Nancy A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^g Jr Hospital of Cook County   (United States)

Author keywords

Highly active antiretroviral therapy; HIV infection; Incidence; Risk factors; Verrucae; Women

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE; RISK FACTOR; SKIN EXAMINATION; SMOKING; VERRUCA VULGARIS; VIRUS LOAD; ADULT; AGE DISTRIBUTION; ANUS DISEASE; CLINICAL TRIAL; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MOUTH DISEASE; MULTICENTER STUDY; SEXUALITY; SKIN DISEASE; UNITED STATES;

ADULT; AGE DISTRIBUTION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANUS DISEASES; CD4 LYMPHOCYTE COUNT; CONDYLOMATA ACUMINATA; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MOUTH DISEASES; RISK FACTORS; RNA, VIRAL; SEXUAL PARTNERS; SKIN DISEASES; UNITED STATES; WARTS;

EID: 50949116967     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283021aa3     Document Type: Article

References (30)

1. Berger TG, Obuch ML, Goldschmidt RH. Dermatologic manifestations of HIV infection. Am Fam Physician 1990; 41:1729-1742.
2. Mirmirani P, Hessol NA, Maurer TA, Berger TG, Nguyen P, Khalsa A, et al. Prevalence and predictors of skin disease in the Women's Interagency HIV Study (WIHS). J Am Acad Dermatol 2001; 44:785-788.
3. Dann F, Tabibian P. Cutaneous diseases in human immunodeficiency virus-infected patients referred to the UCLA Immunosuppression Skin Clinic: reasons for referral and management of select diseases. Cutis 1995; 55:85-88.
4. LeBoit PE. Dermatopathologic findings in patients infected with HIV. Dermatol Clin 1992; 10:59-71.
5. Barton JC, Buchness MR. Nongenital dermatologic disease in HIV-infected women. J Am Acad Dermatol 1999; 40:938-948.
6. Shiboski C, Hilton J, Greenspan D, Westenhouse JL, Derish P, Vranizan K, et al. HIV-related oral manifestations in two cohorts of women in San Francisco. J Acquir Immune Defic Syndr 1994; 7:964-971.
7. Silverberg MJ, Ahdieh L, Munoz A, Anastos K, Burk RD, Cu-Uvin S, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002; 29:427-435.
8. Massad LS, Silverberg MJ, Springer G, Minkoff H, Hessol N, Palefsky JM, et al. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol 2004; 190:1241-1248.
9. Dezube BJ, Pantanowitz L, Aboulafia DM. Management of AIDSrelated Kaposi sarcoma: advances in target discovery and treatment. AIDS Read 2004;14:236-238, 243-244, 251-253.
10. Hermans P. Kaposi's sarcoma in HIV-infected patients: treatment options. HIV Med 2000; 1:137-142.
11. Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer 2004; 100:2644-2654.
12. Costner M, Cockerel l CJ. The changing spectrum of the cutaneous manifestations of HIV disease. Arch Dermatol 1998; 134:1290-1292.
13. Ellis E, Scheinfeld N. Eosinophilic pustular folliculitis: a comprehensive review of treatment options. Am J Clin Dermatol 2004; 5:189-197.
14. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. International Collaboration on HIV and Cancer. J Natl Cancer Inst 2000; 92:1823-1830.
15. Rodrigues LK, Baker T, Maurer T. Cutaneous warts in HIV-positive patients undergoing highly active antiretroviral therapy. Arch Dermatol 2001; 137:1103-1104.
16. Orlando G, Fasolo MM, Signori R, Schiavini M, Casella A, Cargnel A. Impact of highly active antiretroviral therapy on clinical evolution of genital warts in HIV-infected patients. AIDS 1999; 13:291-293.
17. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12:1459-1464.
18. Lillo FB, Ferrari D, Veglia F, Origoni M, Grasso MA, Lodini S, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184:547-551.
19. Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004; 96:1070-1076.
20. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study. Epidemiology 1998; 9:117-125.
21. Bacon MC, von Wyl V, Alden C, Sharp G, Robison E, Hessol N, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 2005; 12:1013-1019.
22. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services, 2004. Updated 3/23/04
23. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998; 177:361-367.
24. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91:226-236.
25. Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996; 174:679-689.
26. Qu W, Jiang G, Cruz Y, Chang CJ, Ho GY, Klein RS, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5R/GP6R primer systems. J Clin Microbiol 1997; 35:1304-1310.
27. Jiang G, Qu W, Ruan H, Burk RD. Elimination of false-positive signals in enhanced chemiluminescence (ECL) detection of amplified HPV DNA from clinical samples. Biotechniques 1995; 19:566-568.
28. Ahdieh L, Gange SJ, Greenblatt R, Minkoff H, Anastos K, Young M, et al. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol 2000; 152:923-933.
29. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570.
30. Freytes DM, Arroyo-Novoa CM, Figueroa-Ramos MI, Ruiz-Lebron RB, Stotts NA, Busquets A. Skin disease in HIV-positive persons living in Puerto Rico. Adv Skin Wound Care 2007; 20:149-150; 152-146.